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ABSTRACT 
Objective: The Vagal-Gamma-Aminobutyric Acid (GABA) theory proposes that some yoga postures and 
breathing practices exert their effects through stimulation of vagal nerves (parasympathetic system) 
with associated brain GABA increases. To evaluate this theory, we compared results from a 12-week 
randomized controlled trial (RCT) of yoga in participants with Major Depressive Disorder (MDD) with 
those of a similar RCT in healthy control participants (HC).
Methods: In an RCT, magnetic resonance spectroscopy (MRS) and mood measures were acquired in 
subjects with MDD (n=15) prior to and following a 12-week yoga intervention. The same measures 
were obtained in the HC (n=17) group. In both studies, thalamic GABA/Creatine was obtained using 
MEGAPRESS at 4 Telsa at baseline (Scan-1), post-intervention (Scan-2), and immediately following a yoga 
session (Scan-3). Clinical scales were completed prior to each scan. 
Results: The MDD-group had significantly lower GABA compared to the HC at baseline (Scan-1, p=0.001), 
but not after 12 weeks of yoga, either before (Scan-2, p=0.12) or after a yoga session (Scan-3, p=0.20). 
Depressive symptoms decreased significantly in the MDD-group (p=0.0001), and anxiety improved in 
both groups. 
Conclusion: After a 12-week yoga intervention, MDD-group mood and anxiety measures improved 
with scores equivalent to those of non-depressed individuals. This study provides the first evidence of 
brain GABA increases associated with specific yoga postures and breathing practices in MDD. These 
results suggest potential benefits of specific yoga postures and breathing practices as monotherapy or 
augmentation to other treatments to reduce anxiety and depression in MDD.
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monoamine systems (serotonin, norepinephrine, 
and dopamine). The vagus nerves contain 
peripheral parasympathetic pathways. Electronic 
vagal nerve stimulation (VNS), a Federal Drug 
Agency (FDA) approved treatment for MDD is 
associated with increases in brain GABA [13,26]. 
Vagal-GABA Theory and VNS both support 
the hypothesis that increased parasympathetic 
activity is associated with increased GABA and 
improved mood. By stimulating vagal nerve 
afferents, yoga-based practices may engage a 
potentially valuable (bottom-up) mechanism for 
treating MDD [27,28]. 
While there is a substantially expanding literature 
on the effects of yoga-based interventions for 
the treatment of depression, this study makes 
novel and substantial contributions by providing 
evidence of non-invasively measured changes in 
brain biochemistry prior to and after completion 
of a manualized yoga-based intervention. 
Specifically, brain GABA levels were measured 
in the thalamus, a deep gray matter structure 
chosen based on established connections to 
regions associated with mood regulation and 
which receives projections from the nucleus 
tractus solitarius, the primary brain stem nucleus 
that receives afferent input from the vagal nerve 
[29]. Furthermore, GABA spectral data were 
acquired at high field (4.0 Tesla, which provides 
excellent spatial and spectral resolution) using 
a gold-standard spectral editing technique, 
MEGAPRESS [30]. GABA data were examined 
relative to mood and anxiety measures. An 
additional, unique contribution of this study is 
the comparison of the robust neurochemistry, 
and mood and anxiety measures obtained from 
a cohort of individuals with MDD data from 
a healthy comparison (HC), non-depressed 
sample before and after a 12-week yoga 
intervention. The following hypotheses were 
evaluated: at baseline prior to the intervention 
the MDD-group would have lower GABA levels 
than HC; over the 12-week intervention MDD-
group GABA levels would increase towards HC 
GABA levels; MDD-group mood and anxiety 
scales would be worse at baseline; and over the 
12-week intervention, MDD-group mood and 
anxiety scales would improve towards those of 
HC. 
Thus, results from this study will help advance 
the field by testing the hypothesis that yoga-
based interventions are not only associated with 
decreases in depressive and anxiety symptoms, 
as previously reported, but with a concomitant 
increase in thalamic GABA levels. These 
Introduction
The World Health Organization Global Burden 
of Disease study estimated that depression is 
the single most burdensome illness during the 
middle years of life
a) Lifetime prevalence for MDD (16.5%) 
and Anxiety Disorders (28.8%) are high, as is 
their co-morbidity 
b) A Transdiagnostic approach takes into 
account the involvement of common patholog-
ical processes in the genesis and maintenance 
of depression and anxiety [1-3]. In random-
ized controlled trials (RCTs) of antidepressants 
in Major Depressive Disorder (MDD), 40 to 
50% of subjects fail to achieve remission. Fur-
thermore, residual symptoms are associated with 
increased risks for recurrence and relapse [4,5]. 
Data from RCTs show benefits of yoga-based 
practices, which include postures (asanas), 
breathing (pranayama), concentration (dharana) 
and meditation (dyharana) [6], for the treatment 
of depression [7,8]. Prior studies support the use 
of yoga-based interventions as adjunctive treat-
ment for MDD [9-12]. 
Gamma-Aminobutyric Acid (GABA), the 
primary human inhibitory neurotransmitter, is 
essential for emotion regulation [13,14]. The 
Vagal-GABA Theory supports a new treatment 
approach for MDD via correction of Autonomic 
Nervous System imbalances (underactive 
Parasympathetic Nervous System and overactive 
Sympathetic Nervous System). Also, MDD is 
associated with low brain GABA levels, measured 
using magnetic resonance spectroscopy (MRS) 
[15,16]. Yoga-based practices are associated 
with increased parasympathetic activity, 
measured by increased heart rate variability 
(HRV) [17-22], increased in vivo brain GABA 
levels [13,23,24], and decreased symptoms of 
depression and anxiety [25]. The presence of 
low parasympathetic and GABA activity in both 
MDD and anxiety disorders suggests shared 
physiological abnormalities [13]. These findings 
provide supporting evidence for mechanisms 
whereby yoga-based interventions reduce 
symptoms of MDD and anxiety. Moreover, 
these mechanisms are consistent with the Vagal-
GABA Theory, which supports a transdiagnostic 
conceptualization of disorders with low 
parasympathetic and GABAergic activity. 
By correcting under activity in parasympathetic 
and GABA systems, yoga-based practices may 
complement conventional antidepressants, 
whose benefits have been attributed to effects on 
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observations provide a biological, translational 
framework through which yoga-based practices 
can be used to better understand the mechanism 
underlying associated improvements in mood 
and decreases in depressive and anxiety related 
symptoms.
Materials and Methods
  Participants
This study compares the same outcome measures 
from two separate cohorts, MDD and HC, 
acquired in two separate studies. The RCT 
comparing yoga with walking provided a yoga 
cohort of 17 HC (9 females) who completed the 
intervention and three MRS scans between 2007-
2009 [24]. The RCT of MDD was completed 
between 2013-2015, using the same manualized 
yoga postures intervention, the same data 
collection time course and the same 4.0 Tesla 
scanner and methods for spectral acquisition, 
processing, and analysis [25]. The RCT of 
MDD included two yoga groups: a high dose 
group (n=15, 13 female) and a low dose group 
(n=15, 12 female). The low dose group served as 
the MDD-group in this analysis because the low 
dose group yoga posture dose was equivalent to 
the yoga posture dose for HC (see Supplement). 
Participants for both RCTs were recruited 
from the community via Internet, newspaper 
ads and flyers. The Boston University Medical 
Center (BUMC) Campus Institutional Review 
Board approved both research protocols. All 
participants received complete study description 
and provided written informed consent. See the 
Participant Flow Diagram (Figure 1).
In summary, inclusion and exclusion criteria 
were similar across groups, except that the HC 
did not meet criteria for MDD, while the MDD-
group met current diagnostic criteria for MDD, 
determined by the Structured Clinical Interview 
for DSM-IV [31] and Beck Depression Inventory-
II (BDI-II) score ≥ 14 at screening [32]. Of the 
15 participants with MDD, 5 also met criteria 
for Post-Traumatic Stress Disorder (PTSD) (2 
current, 3 partial/full remission), 2 met criteria 
for Panic Disorder in partial remission; 2 met 
criteria for Alcohol Abuse, and 2 met criteria 
for Alcohol Dependence (all in remission). One 
female participant in the MDD group was on 
a stable dose of the antidepressant venlafaxine 
(150 mg), a serotonin-norepinephrine reuptake 
inhibitor (SNRI). Full descriptions of inclusion 
and exclusion criteria are detailed below. 
  Inclusion and exclusion criteria: healthy 
control (HC) group 
Inclusion Criteria for HC-group included: ages 
18-45 years old; no current Axis-I diagnosis; non-
psychoactive medications allowed if participants 
had been on a stable dose for at least 1 month 
with no anticipated changes during the study. 
The following items were exclusionary for the 
HC-group: any yoga practice in the previous 3 
months or a lifetime history of one yoga session/
week for ≥ 4 weeks; current participation in 
psychotherapy, prayer groups, or any mind-body 
disciplines; a neurological disorder or medical 
condition that would compromise subject safety 
or scan data; treatment within the previous 3 
months with medications that might affect the 
GABA system; use of tobacco products (known 
to affect GABA levels); alcohol consumption 
of >4 drinks/day in the past 90 days (known 
to effect GABA levels); contraindications for 
magnetic resonance evaluation; and inability 
to complete the study or behavior that would 
compromise study integrity.
  Inclusion and exclusion criteria: MDD 
group
Inclusion criteria for the MDD-group included: 
ages 18 to 65 years old; current diagnosis of MDD 
determined by Structured Clinical Interview for 
DSM-IV; BDI-II score ≥ 14 at screening (at least 
mild depression); co-morbid anxiety disorder(s) 
were allowed if they would not interfere with 
study participation; a stable dose (no change in 
the amount) of antidepressants for at least three 
months prior to screen and no dosing changes 
were anticipated during the study. Exclusionary 
criteria for the MDD-group were the same as the 
HC with the following exceptions due mostly to 
the exclusion of all current Axis I disorders in the 
HC: bipolar illness; history of psychosis; suicide 
attempt in the last year or suicidal ideation with 
intent within the last year; and current alcohol 
or substance abuse or dependence. Mood 
stabilizers were excluded due to potential effects 
on GABA levels. Exclusion based on prior yoga/
mind-body practice was >6 one-hour mind-body 
practices over the past 6 months prior to study 
participation.
  Study protocol
Both studies were conducted at BUMC, and 
MRS data were acquired in the Brain Imaging 
Center at McLean Hospital (Belmont, MA). 
In both RCTs, participants completed similar 
12-week yoga postures protocols [24,25]. In 
Neuropsychiatry (London)   (2018) 8(6)1926
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Figure 1: Participant Flow Diagram. Analysis of two RCT studies drew the HC group from the Yoga versus Walking RCT and the MDD-group from the 
Yoga for MDD Dosing RCT. 
Abbreviations: RCT: Randomized Controlled Study; HC: Healthy Controls; MDD: Major Depressive Disorder; LDG: Low Dose Group; HDG: High Dose 
Group; WG: Walking Group; YG: Yoga Group
*Note: N=19 YG completed, However N=2 had incomplete MRS data, resulting in N=17 YG for GABA comparisons.
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addition to yoga postures, the protocol for the 
MDD group included coherent breathing. For 
the purposes of this report, the term yoga refers 
to postures or postures and coherent breathing 
practices. Both studies used CONSORT 
guidelines, promoting high quality RCTs that 
allow comparisons between studies [33]. See 
Supplementary Material for randomization 
codes, random allocation sequence, intervention 
assignment, blinding, and CONSORT 
Checklist.
All participants completed initial screening and 
three MRS brain-imaging sessions. The first MRS 
acquisition (Scan-1) was conducted at baseline, 
prior to the onset of the yoga intervention. After 
completion of the 12-week yoga intervention, 
two subsequent MRS acquisitions (Scan-2 and 
Scan-3) and a yoga intervention between Scan 2 
and Scan 3 were completed on the same day at 
the Brain Imaging Center. Scan-2 was acquired 
before a yoga session and Scan-3 was acquired 
immediately after the yoga session (Figure 2). 
Groups did not differ significantly in the length 
of time between Scan-1 and Scan-2/Scan-3, 15.6 
± 3.1 weeks for the HC-group and 14.1 ± 1.3 
weeks for the MDD group. The time (number 
of days) between the last yoga intervention and 
Scan-2/Scan-3 was 7.1 ± 1.8 days for the MDD-
group; this information was not available for the 
HC group.
Menstrual cycle hormones affect brain GABA 
levels [34,35]. Thus, females were scanned 
during the non-luteal stage of the menstrual cycle 
when progesterone levels were low and stable, 
confirmed by serum progesterone level <0.3 ng/
ml, drawn several days prior to scanning. 
  12-Week interventions
All participants completed 60-min Iyengar yoga 
sessions, including backbends and inversions, 
postures considered beneficial for treating 
depression, and savasana (deep relaxation while 
lying supine). In addition to the 60-min yoga. 
intervention, the MDD-group completed a 10-
min transition and 20-min coherent breathing 
exercise at 5 breaths per minute with equal 
inhalation and exhalation, guided by audio 
compact disc (high tone for inhalation and low 
tone for exhalation) [36-38]. The yoga sessions 
between Scan-2 and Scan-3 were the same as a 
class session for each group. Study intervention 
details have been previously published [24,25]. 
The HC group was assigned three 60-min classes 
plus 60-min of homework each week [24]. The 
MDD-group was assigned to two 90-min classes 
and three 30-min homework assignments per 
week. Homework consisted of 15-min of yoga 
postures and 15-min of coherent breathing. 
There were no significant differences in the total 
number of yoga classes or posture time between 
the HC yoga group and the MDD low dose 
group. This analysis compares data from HC-
cohort and the MDD-group. 
  Assessment of mood and depressive 
symptoms
BDI-II scores, representing depressive symptoms 
within the prior two weeks, were acquired at 
screening and before Scan-1 and Scan-3 [32]. 
Current mood was assessed prior to each scan 
by Spielberg State-Trait Anxiety Inventory 
State (STAI-State) [39] and Exercise-Induced 
Feeling Inventory (EIFI) [40] with four 
subscales: Tranquility, Positive Engagement, 
Revitalization, and Physical Exhaustion.
  Magnetic resonance imaging (MRI)/
Magnetic resonance spectroscopy (MRS)
MRI and proton (1H) MRS scans were acquired 
on 4.0-Tesla Varian Unity/INOVA whole-body 
Figure 2: Study Timeline: Yoga Intervention, Mood Measures, and MRS and Assessments. 
All participants completed initial screening, assessments, and baseline MRS acquisition (Scan-1) prior to starting the yoga interventions. After the 12-week 
yoga interventions, participants completed assessments, the second MRS acquisition (Scan-2), followed immediately by a single yoga session and the third 
MRS acquisition (Scan-3).
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MRI/MRS scanner (Varian Inc., Palo Alto, 
California) using a volumetric head coil (XLR 
Imaging, London, Canada) in the Brain Imaging 
Center at McLean Hospital. Head placement was 
confirmed using three-plane scout images. High-
contrast 3D fast low-angle shot T1-weighted 
images were collected for voxel placement, 
followed by global shimming, and placement of 
a 20 (left to right) x 20 (inferior to superior) x 
30 (anterior to posterior)-mm voxel in the left 
thalamus, whose inferior aspect was aligned with 
the Anterior Commissure-Posterior Commissure 
(AC-PC) line on sagittal view, and the medial 
aspect of the central sulcus and anterior aspect of 
the corpus callosum on axial view (Figure 3A). 
Manual voxel shimming of the thalamic voxel 
yielded an average water line width = 10.6 ± 3.9Hz, 
which did not differ significantly between groups 
or across scan sessions. MEGAPRESS [30,41] 
was used to obtain difference-edited GABA-
optimized spectra, as described previously [35]. 
The 3.00-ppm GABA doublet resonance and co-
edited resonance structures of glutamate (Glu), 
glutamine (Gln), N-acetylaspartate (NAA), and 
the 0.93-ppm macromolecule (MM) resonance 
from MEGAPRESS 68 ms and difference-edited 
spectra were fitted using LCModel [42] (Figures 
3B and 3C). Within-subject coefficients of 
variation (CV=standard deviation/mean) using 
MEGAPRESS in the thalamus for GABA was 
9.5% [43]. Average GABA Cramer Rao Lower 
Bounds (CRLB) in the present study was 9.0 ± 
2.9%, which did not differ significantly between 
groups or scan-time  (F (2,60) = 2.53 p=0.09). 
While GABA was the a  priori of interest, 
other 68ms “OFF” subspectra metabolites were 
examined to verify MRS reliability, and to rule 
out systematic metabolite differences. There were 
no significant CRLB differences between groups 
or scan-time for Creatine (Cr) (1.8 ± 0.5%, F 
(2,60)=0.71, p=0.92), NAA (2.0 ± 0.8%, F 
(2,60)=0.75, p=0.93), or choline (Cho) (14.5 ± 
11.8%, F (2,40)=0.34, p=0.72). There were no 
main effects of group or scan-time for CRLB 
(pooled Glu+Gln: 25.1 ± 10.4%), although 
there was a significant interaction (F(2,60)=4.37, 
p=0.02). All metabolite ratios were determined 
using Cr as the denominator.
T1-weighted axial image sets were segmented 
into gray matter (GM), white matter (WM), 
and cerebrospinal fluid (CSF) binary-tissue 
maps (FSL, Oxford, United Kingdom), with 
partial tissue percentages extracted for each 
voxel [43,44] to quantitatively estimate potential 
tissue-percentage differences on GABA/Cr 
ratios, which only correct for total tissue content 
[45,46]. Tissue percentages also were compared 
to confirm reliability of voxel placement across 
MRS scans.
  Statistical analyses
Statistical analyses were conducted using SPSS 
24.0 (SPSS, Chicago, Illinois). Two group 
(HC, MDD) univariate analyses of variance 
(ANOVAs) and covariance (ANCOVAs) 
evaluated mood and depression scores, and 
thalamic GABA at baseline (Scan-1). Repeated 
measures ANOVAs/ANCOVAs assessed changes 
from baseline (Scan-1) to after completion of the 
12-week intervention (Scan-2) and immediately 
after a yoga session (Scan-3). Post-hoc tests 
(two-tailed t-tests) were conducted to investigate 
sources of differences in analyses with significant 
main effects and/or interactions. Given the a 
priori hypothesis regarding changes in GABA/Cr 
over the course of the intervention, one-tailed 
paired t-tests were performed for each group 
to examine whether GABA changes between 
scans were statistically significant. Cohen effect 
sizes f (ES) were calculated for significant main 
effects and interactions using G*power (Version 
3.1.9.2.). Pearson’s correlation coefficients were 
used to examine relationships between GABA/
Cr and clinical variables. Alpha levels were set at 
=0.05, except for metabolite analyses, wherein 
the p-value for each metabolite was corrected to 
account for multiple comparisons (GABA, Cho, 
GLX, and NAA) via a modified Bonferroni 
procedure [47], yielding an adjusted alpha level 
=0.016, based on four metabolites and average 
inter-correlation coefficients (r=0.178). Age, 
gender, and GM content (or WM content for 
analysis of the WM metabolite Cho) produced 
no significant effects when included as covariates, 
and were removed from statistical models. 
Results
  Group demographics
HC-group was significantly younger and had 
significantly lower body mass index (BMI) than the 
MDD-group. No other significant between-group 
demographic differences were found (Table 1).
  Yoga intervention attendance
There was no significant difference in the number 
of classes or in class posture minutes for HC 
compared to MDD-group (Table 2) (p=0.18). 
However, total yoga minutes were significantly 
greater in the MDD-group F(1,30)=6.66, 
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Figure 3: MRS Voxel Placement and Proton Spectra. 
(A) Sagittal image illustrating placement of 20 x 20 x 30 mm single voxel in the left thalamus. Sample raw (no exponential filter) spectral thalamic data: (B) 68 
ms spectrum and (C) difference-edited  GABA spectrum acquired using MEGAPRESS. 
Abbreviations: Cho: Choline; Cr: Creatine; GABA: Gamma-Aminobutyric Acid; GLX: Glutamate + Glutamine; Glu, Glutamate; Mi: Myo-Inositol; MM: 
Macromolecule; MRS: Magnetic Resonance Spectroscopy; NAA: N-Acetyl-Aspartate.
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p=0.015, ES=.46), due to an additional 30 min of 
class time for transition and coherent breathing. 
Differences in methods for documenting yoga 
homework in HC compared to MDD-group 
precluded statistical comparison (Table 2). 
  MRI/MRS metabolite data 
No significant differences appeared for either 
group in tissue segmentation data across Scans-1, 
2 or 3, GM (48.4 ± 15.2%, F(2,60)=0.34, 
p=0.72), WM (41.3 ± 21.4%, F(2,60)=0.16, 
p=0.85), CSF (12.2 ± 14.8%, F(2,60)=0.11, 
p=0.90), or total tissue percentage (88.7 ± 
12.6%, F(2,60)=0.14, p=0.87), confirming 
reproducibility of thalamic voxel placement 
algorithm across MRS sessions. Raw spectral 
areas did not differ significantly between 
groups or scan-times for 68ms Cr (131.9 ± 
29.5, F(2,60)=1.08, p=0.35), indicating Cr 
was an unbiased denominator for metabolite 
ratios. Full width half max (0.07 ± 0.01, F(2, 
60)=1.08, p=0.39, p=0.68) and signal-to-noise 
ratios [SNR; height of NAA/noise standard 
deviation in residual] (50.2 ± 9.6, F(2,60)=0.51, 
p=0.95) did not differ significantly across scans 
or between groups. Nineteen HC completed 
the intervention; two had incomplete scan data, 
resulting in 17 HC for analysis.
  Changes in GABA across the 12-week 
yoga intervention
Figure 4 shows spectra from one MDD 
participant illustrating GABA peak increases 
from baseline (Scan-1), post 12-week yoga 
intervention (Scan-2), and immediately after an 
intervention (Scan-3). Scan-3 spectra from one 
MDD participant approximate baseline spectra 
(Scan-1) from one HC participant.
Table 1: Participant Demographics.
Measures MDD (n=15) HC (n=17) P Value
Age (years) 34.7 ± 10.4 23.9 ± 3.2 <0.001*
Female/male 12/3 9/8 0.11
Race
Caucasian 87% 88%
African American 13% 6%
Asian 0% 6%
Years of Education 16.7 ± 2.1 16.4 ± 1.1 0.98
BMI 28.1 ± 5.6 22.9 ± 2.8 0.03**
Data represent mean values ± standard deviation. Abbreviations: HC: Healthy Controls; MDD: Major Depressive Disorder; BMI: Basal Metabolic Index. 
*F(1,30)=16.45, p<0.001, ES=0.79, ** F(1,30)=11.42, p<0.005, ES=0.62.
Table 2: Yoga Intervention.
Measures
Classes MDD (n=15) HC (n=17) P Value
Class Length (min) 90 60
Classes Assigned 24 36
Total Minutes Assigned 2160 2160
Classes Attended 20.5 ± 4.5 23.6 ± 7.5 0.18
Total Minutes 1,818.0 ± 431.9 1,415.3 ± 448.0 0.015
Total Posture Minutes 1,232.0 ± 267.2 1,415.3 ± 448.0 0.18
Total Coherent Breathing (min) 616.0 ± 133.6 N/A
Homework MDD (n=15) HC (n=17) P Value
Homework Assigned (min per week) 90 60
Total Homework Assigned (min) 1,080 720
Total Homework Reported (min) 919.1 ± 474.8 ----
Homework Postures MDD (n=15) HC (n=17) P Value
Total Postures Assigned (min) 540 720
Sessions Reported 25.5 ± 11.8 ----
Total Postures Reported (min) 555.9 ± 294.0 ----
Homework Coherent Breathing MDD (n=15) HC (n=17) P Value
Total Breathing Assigned (min) 540 N/A
Sessions Reported 23.5 ± 14.2 ----
Total Minutes Reported 363.1 ± 229.6 ----
Data represent mean values ± standard deviation. Abbreviations: HC: Healthy Controls; MDD: Major Depressive Disorder; min: minutes.
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Figure 4: Thalamic GABA Spectra. 
Representative spectra from one participant in the MDD-group at baseline (Scan-1, blue spectrum), after 12-week intervention (Scan-2, orange spectrum) and 
post-session (Scan-3, red spectrum) are compared with baseline spectrum (Scan-1, black spectrum) from one HC subject. 
Abbreviations: GABA: Gamma-Aminobutyric Acid; HC: Healthy Controls; MDD: Major Depressive Disorder
At baseline, GABA/Cr was significantly lower in 
the MDD-group (0.26 ± 0.06) compared to the 
HC group (0.33 ± 0.05). Post-hoc analyses of 
group comparisons post 12-week intervention 
(Scan-2) and immediately after a yoga session 
(Scan-3) showed that GABA/Cr differences 
between HC and MDD-groups were no longer 
statistically significant (Figure 5). One-tailed, 
paired t-tests revealed that while the change in 
GABA/Cr did not differ significantly for either 
group from Scan-1 to Scan-2 (HC: -0.01 ± 0.08, 
p=0.27; MDD: 0.02 ± 0.10, p=0.20), changes in 
GABA/Cr were significant from Scan-1 to Scan-
3 (HC: 0.03 ± 0.07, t16=1.75, p=0.05, ES=.43; 
MDD:0.06 ± 0.10, t14=2.513, p=0.013, 
ES=.60) and from Scan-2 to Scan-3 (HC: 0.04 
± 0.09, t16=1.91, p=0.04, ES=.44; MDD: 0.04 
± 0.08, t14=1.99, p=0.034, ES=.50) for both 
groups (Figure 5). There was a significant effect 
of scan-time for GABA/Cr, from baseline (Scan-
1) to post 12-week intervention (Scan-2) and 
immediately after a yoga session (Scan-3) (F(2, 
60)=5.53, p=0.006, ES=.43), and a main effect 
of group (F(1,30)=14.08, p=0.001, ES=0.37.) 
However, no significant scan-time x group 
interaction was observed (F(2,60)=0.82, p=0.45).
  Changes in NAA, GLX and choline
For other proton metabolites, significant 
differences by group were observed at baseline for 
GLX (Scan-1, F(1,30)=7.94, p=0.008, ES=.45) 
and NAA (Scan-1, F(1,30)=5.84, p=0.02, 
ES=.40), but not for Cho (Scan-1, F(1,30)=0.55, 
p=0.46) (Table 3). NAA, Cho or GLX did not 
change significantly between Scans-1 and Scan-
3 (F(2,58)=0.29, p=0.75; F(2,38)=1.00, p=0.38, 
F(2,58)=0.41, p=0.67, respectively).
  BDI-II, STAI-State and EIFI outcomes 
An effect of scan-time was evident in the 
MDD-group for BDI-II scores, which declined 
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Figure 5: Changes in Thalamic GABA/Cr in MDD and HC. 
Significantly lower GABA/Cr in the MDD-group (blue bars) compared to HC group (red bars) at baseline (Scan-1: F1,30=13.38, p=0.001, ES=.55). Non-
significant group differences observed after 12-week intervention (Scan-2: F1,30 p=0.10) and post-yoga session (Scan-3: F1,30=p=0.30). *denotes 
statistically significant differences between groups for Scan-1; **denotes statistically significant change from Scan-1 to Scan-3 and from Scan-2 to 
Scan-3 in both groups. 
Abbreviations: GABA: Gamma-Aminobutyric Acid; Cr: Creatine; HC: Healthy Controls; MDD: Major Depressive Disorder
Table 3: Metabolite: Cr Ratios.
Group Metabolite BaselineScan-1
12-Weeks
Scan-2
Post Yoga
Scan-3
MDD
(n=15)
GABA/Cr 0.26 ± 0.06* 0.28 ± 0.06** 0.32 ± 0.07***
Cho/Cr 0.67 ± 0.04 0.66 ± 0.04 0.65 ± 0.03
GLX/Cr 1.04 ± 0.05 1.01 ± 0.06 1.12 ± 0.07
NAA/Cr 1.44 ± 0.05 1.48 ± 0.05 1.55 ± 0.06
HC
(n=17)
GABA/Cr 0.33 ± 0.05 0.32 ± 0.06** 0.36 ± 0.07***
Cho/Cr 0.63 ± 0.04 0.55 ± 0.04 0.61 ± 0.03
GLX/Cr 1.33 ± 0.09 1.24 ± 0.07 1.30 ± 0.11
NAA/Cr 1.60 ± 0.04 1.54 ± 0.03 1.57 ± 0.04
Data represent mean values ± standard deviation. Abbreviations: Cho: Choline; Cr: Creatine; GABA: Gamma-aminobutyric acid; GLX: Glutamate + 
glutamine; NAA: N-acetyl-aspartate; HC: Healthy Controls; MDD: Major Depressive Disorder. *denotes statistically significant group difference 
between MDD and HC (p<.05); **statistically significant change from Scan-1 to Scan-2 for both groups; ***statistically significant change from Scan-1 
to Scan-3 for both groups
significantly from baseline (Scan-1) to post 12-
week intervention (Scan-3) (F(2,28)=29.26, 
p<0.0001, ES=1.44) (Figure 6a). There was a 
significant effect for scan-time (F(2,56)=13.58, 
p<0.0001, ES=0.70) and scan-time x group 
interaction (F(2,56)=3.71, p=0.03, ES=.36) 
for STAI-State scores (Table 4 and Figure 
6b). Post hoc comparisons revealed significant 
declines in STAI-State scores over scan-times 
in both groups (Table 5). Significantly higher 
STAI-State scores at Scan-1 in the MDD-
group compared to HC were no longer 
significantly different at Scan-2 or Scan-3. Post 
hoc tests for STAI-State revealed significant 
differences between the MDD and HC groups 
at Scan-1 and Scan-2, which were no longer 
observed at Scan-3. A significant decrease in 
STAI-State scores was observed in the MDD-
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Figure 6: Beck Depression Inventory-II (BDI-II) and State-Trait Anxiety Inventory (STAI) State Scores. 
(A) BDI-II scores declined significantly in the MDD-group. (B) STAI State scores decreased significantly, and with greater magnitude in the MDD-group 
compared to HC. 
Abbreviations: HC: Healthy Controls; MDD: Major Depressive Disorder
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Table 4: Effect of Scan-Time on State Trait Anxiety (STAI) State and Exercise Induced Feeling Inventory (EIF).
Effect of Scan-Time Test Df P Value ES
STAI-State F=13.58 2,56 <0.0001* 0.70
EIFI: Positive Engagement F=8.51 2,54 0.001* 0.56
EIFI: Revitalization F=35.21 2,54 <0.001* 1.14
EIFI: Tranquility F=18.56 2,54 <0.0001* 0.83
EIFI: Physical Exhaustion F=9.66 2,54 <0.0001* 0.60
Effect of Scan-Time x Group Test Df P Value ES
STAI-State F=3.71 2,56 0.03* 0.36
EIFI: Revitalization F=5.08 2,54 0.01* 0.43
EIFI: Tranquility F=7.07 2,54 0.002* 0.51
Table 5: Post Hoc Analyses.
Post Hoc Analysis
MDD Scores Lower than HC Scores Test Df P Value ES
EIFI: Positive Engagement
Scan 1 t=2.67 28 0.01* 0.97
Scan 2 t=3.67 28 0.001* 1.34
  Scan 3 28 0.37
EIFI: Revitalization
Scan 1 t=2.48 28 0.02* 1.48
Scan 2 t=4.05 28 <0.001* 0.91
Scan 3 28 0.50
EIFI: Tranquility
Scan 1 t=3.17 28 28 0.004* 1.16
Scan 2 t=4.77 28 28 <0.001* 1.74
Scan 3 t=0.91 27 0.37
MDD Scores Higher than HC Scores Test Df P Value ES
EIFI: Physical Exhaustion
Scan 1 t=-1.02 28 28 0.32
Scan 2 t=-0.54 28 28 0.59
Scan 3 t= 0.59 27 27 0.56
MDD and HC Increases Scan 1 to Scan 3 Test 
Df P Value ES Test Df P Value ES
EIFI: Positive Engagement F=13.53 1,27 0.001 0.71
EIFI: Revitalization F=54.85 1,27 <0.001 1.43
EIFI: Tranquility F=31.47 1,27 <0.001 1.08
MDD Increase Scan 2 to Scan 3 Test Df P Value ES
EIFI: Positive Engagement t=2.32 14 0.04 0.6
EIFI: Revitalization t=6.97 14 <0.001 1.80
EIFI: Tranquility t=5.44 14 <0.001 1.41
MDD Decreases Scan 1 to Scan 2 Test Df P Value ES
STAI-State t=4.33 14 0.001 1.12
EIFI: Physical Exhaustion t=3.15 14 0.007 0.81
MDD and HC Decreases Scan 2 to Scan 3 Test Df P Value ES
MDD Group: STAI-State t=4.33 14 0.001 1.12
HC Group: STAI-State t=2.02 14 0.06 0.52
MDD EIFI: Physical Exhaustion t=2.97 14 <0.001 0.65
group and a trend for a decrease was evident in 
HC between Scan-2 and Scan-3.
There were significant effects of scan-time for EIFI 
subtests: Positive Engagement, Revitalization, 
Tranquility and Physical Exhaustion (Table 4 
and Figure 7). Significant scan-time x group 
interactions were evident for Revitalization and 
Tranquility. Post hoc analyses revealed the MDD-
group EIFI was lower than HC at Scan-1 and 
Scan-2 for Positive Engagement, Revitalization 
and Tranquility but no longer different at Scan 
3. Further, both MDD and HC group scores on 
all three measures increased significantly between 
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Scan-1 and Scan-3 for Positive Engagement, 
Revitalization, Tranquility, but only the MDD-
group had significantly increased scores between 
Scan-2 and Scan-3 for Positive Engagement, 
Revitalization, and Tranquility. Conversely, 
only the MDD-group showed significant decline 
in Physical Exhaustion from Scan-1 to Scan-2 
and from Scan-2 to Scan-3.
Discussion
In accord with prior yoga RCTs for treatment 
of depression [7,10,25,48,49], this comparative 
analysis found improved mood and anxiety after 
12-weeks of a yoga intervention in participants 
with MDD. In the MDD-group, following 
the yoga intervention, thalamic GABA levels 
increased (normalized) while depressive symptoms 
(lower BDI-II scores) and anxiety (lower STAI-
State scores) both diminished. This study 
provides important, novel information regarding 
enhanced neurochemistry following a yoga-based 
intervention, measured as significantly increased 
thalamic GABA levels in the MDD group, 
equivalent to levels observed in a healthy, non-
depressed cohort. These findings support the Vagal-
GABA Theory of depression, which postulates 
that specific yoga postures and breathing practices 
associated with improved mood are accompanied 
by increased GABA activity [13,24,25].
Figure 7: Comparison of Exercise Induced Feeling Inventory (EIFI) Scores for MDD and HC Groups.
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Thalamic GABA was the primary dependent 
variable of this comparative analysis. Thalamic 
GABA levels in the MDD-group compared to 
the Hyphenate: HC-group were statistically 
significantly lower at baseline (Scan 1) but 
were no longer statistically different after the 
yoga intervention at Scan-2 and Scan-3. The 
yoga-associated GABA increases in the MDD-
group were robust, producing medium to large 
effect sizes (effect size F: .25 to .40; effect size 
d/dz: .50 to .80) with p-values that withstood 
correction for multiple comparisons (p=0.006 
at baseline, p=0.001 change over treatment). 
Clinical outcome measures in the MDD-group 
also normalized: EIFI subscales Tranquility, 
Revitalization and Positive Engagement 
increased, while Physical Exhaustion decreased. 
Symptoms of MDD declined significantly 
on BDI-II. Symptoms of anxiety declined 
significantly on the STAI-State. Most changes 
in clinical outcome measures were robust, 
producing large effect sizes. 
Low parasympathetic and low GABA activity are 
reported in MDD [16,50], post-traumatic stress 
disorder (PTSD) [51,52], panic disorder [53-
55], epilepsy [56,57] and alcohol dependence 
[58,59]. These disorders are frequently comorbid 
suggesting transdiagnostic, common core core 
abnormalities: low parasympathetic and low 
GABA activity [13]. In addition to MDD, 
evidence from RCTs suggests that yoga-based 
interventions can reduce symptoms of PTSD 
[60-62] and anxiety disorders [63,64]. As 
these disorders share common abnormalities, 
low parasympathetic and GABA activity, the 
potential benefits of yoga-based practices may 
be generalizable to other disorders with low 
parasympathetic and GABA activity. 
Baseline levels of GLX and NAA were lower in 
the MDD-group. The difference in NAA did not 
survive multiple comparison correction. GLX 
and NAA did not change significantly over the 
course of treatment. Cho showed no between-
group difference at baseline or post-intervention. 
These findings indicate that yoga-related changes 
in brain metabolites were GABA specific, rather 
than reflecting general or systematic increases. 
These results are consistent with previous studies in 
MDD documenting altered GABA levels [50] and 
mixed findings for other proton metabolites [65].
These findings should be tempered by the 
strengths and weaknesses of the studies, as well as 
the analysis. Strengths include use of CONSORT 
criteria, allowing comparisons across RCTs in 
HC and MDD cohorts (see Supplement). The 
research team, recruitment environments, yoga 
interventions and MRS (scanner, sequence, and 
data processing) were similar. There also were no 
differences over repeated scans for either group 
regarding reliability of voxel placement, signal-
to-noise, reliability of spectral fitting, or tissue 
composition within the MRS voxel. Additional 
strengths include the use of a manualized yoga 
intervention, highly trained Iyengar yoga 
instructors, fidelity assessments, and adverse 
events reporting. One weakness is the lack of 
temporal overlap for data collection from the 
two cohorts. Another limitation is the addition 
of coherent breathing to the yoga intervention 
for the MDD-group only, which increased 
overall class time to 90 min (30 min longer 
than in HC), although minutes of posture class 
time between the groups was not significantly 
different. The extent to which coherent breathing 
contributed to intervention-related effects 
cannot be determined in the current analysis, but 
warrants further study. Lastly, the MDD-group 
was older and had a higher BMI compared to 
HC. Nevertheless, significant baseline GABA 
differences were maintained when analyses were 
adjusted for age. 
The results of this study must be interpreted 
with consideration of the severity of participant 
symptoms. Because yoga is not an approved 
treatment for depression, individuals with 
suicidal ideation with intent (past year) were 
excluded. In addition, individuals with a level of 
depression severity that could have affected their 
ability to complete the study were excluded. 
Accordingly, conclusions can only be drawn 
about individuals with depression who met study 
inclusion criteria. The MDD-group, of which 
only 1 was on an antidepressant medication, 
demonstrated a significant decrease in depressive 
symptoms, suggesting a potential benefit of 
specific yoga postures and breathing practices 
to augment other treatments, and to reduce 
depressive symptoms in MDD populations 
similar to those enrolled in this study. Additional 
neurobiological investigations of yoga-based 
interventions for reduction of symptoms 
associated with other disorders known to have 
low brain GABA levels, such as PTSD and 
anxiety disorders, are warranted.
In conclusion, comparative analysis of cohorts 
from two RCTs using a similar 12-week yoga 
intervention found that in the MDD-group, 
depression and anxiety measures improved to 
levels equivalent to those of the non-depressed 
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healthy control (HC). Concurrently, thalamic 
GABA levels, which were comparatively low 
at baseline in the MDD-group, increased 
significantly to levels no longer significantly 
different from those of healthy controls. This 
study provides the first evidence in participants 
with MDD of increases in brain GABA levels 
and decreases in depressive symptoms associated 
with a yoga intervention. These results indicate 
potential benefits of specific yoga postures 
and breathing practices as monotherapy or 
augmentation to other treatments to reduce 
anxiety and depression in MDD. Furthermore, 
yoga-based interventions offer potential 
treatments for other disorders with low brain 
GABA such as PTSD and other anxiety disorders. 
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